Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy

Table 1 General information of patients in groups A and B

	Group A (n = 29)	Group B (n=38)	P value
Age (yr)	53.83 ± 2.20	55.26 ± 6.67	P > 0.05
Sex (male/female)	24/5	32/6	P > 0.05
Tumor size (cm)	7.58 ± 2.50	7.76 ± 3.13	P > 0.05
Preoperative interval (d)	23.34 ± 2.45	21.79 ± 4.19	P > 0.05
HbsAg positive rate (%)	75.9	81.58	P > 0.05
α-FP positive rate (%)	65.5	72.97	P > 0.05
Microvenous carcinoma embolus rate (%)	10.3	13.16	P > 0.05

Table 2 Postoperative complications in patients with and without P³²-GMS radiotherapy, n (%)

Complications	Group A (n = 29)	Group B (n = 38)	P value
Liver failure	3 (10.3)	3 (7.89)	P > 0.05
Perioperative death	0	0	P > 0.05
Subdiaphragm infection	1 (3.45)	2 (5.26)	P > 0.05
Bile leakage	0	0	P > 0.05
Leukopenia	0	0	P > 0.05
Jaundice	1 (3.45)	2 (5.26)	P > 0.05
Liver wound rupture	0	0	P > 0.05
Pleural effusion and/or ascites	5 (17.24)	5 (13.15)	P > 0.05

Table 3 HCC recurrence rates in patients with and without P³²-GMS, n (%)

Postoperative intervals	Group A (n = 29)	Group B (n = 38)	P value
6 mo	4 (13.8)	15 (39.5)	P = 0.021a
1 yr	7 (24.1)	20 (52.6)	P = 0.018a
2 yr	13 (44.8)	29 (76.3)	P = 0.008b
3 yr	18 (62.1)	33 (86.8)	P = 0.018a
Over 3 yr	18 (62.1)	33 (86.8)	P = 0.018a

^aP < 0.05;

^bP < 0.01.

Table 4 Survival rates in patients with and without P³²-GMS, n (%)

Postoperative intervals	Group A (n = 29)	Group B (n = 38)	P value
6 mo	28 (96.6)	35 (92.1)	P = 0.454
1 yr	27 (79.3)	27 (71.1)	P = 0.024a
2 yr	22 (75.9)	17 (44.7)	P = 0.010b
3 yr	19 (65.5)	8 (21.1)	P = 0.000b
Over 3 yr	14 (48.3)	8 (21.1)	P = 0.018a

^aP < 0.05;

^bP < 0.01.